How to Document Compensating Controls When Legacy Medical Devices Can’t Be Patched

Compensating Controls Definition

Compensating controls are risk-reducing safeguards you implement when a vulnerability cannot be fixed by patching. For legacy medical devices, that often means using alternative technical, administrative, and physical measures to achieve an equivalent or acceptable security outcome without altering the device software or firmware.

In practice, you reduce the attack surface around the device and tightly govern how it connects, who can access it, and what it can do. Strong documentation links each control to a specific threat, explains why patching is infeasible, and maps the control to relevant compliance frameworks and patient safety objectives.

• Administrative: policies, workflows, user training, and maintenance procedures.
• Technical: network segmentation, allowlisting, virtual patching with IPS, strict authentication, and encryption where supported.
• Physical: locked locations, tamper seals, and controlled service access.

Documentation Requirements

Your record should meet rigorous documentation standards so auditors, engineers, and clinicians can understand what you did and why. Treat it like a controlled quality document with versioning, approval history, and traceability to risks and requirements.

• Asset identity: manufacturer, model, OS/version (if known), serial/UDI, location, clinical owner, support status/EoL, and network identifiers.
• Vulnerability detail: description, exposure path, known exploits, severity rationale, and the specific clinical hazards implicated.
• Why patching isn’t possible: vendor constraints, validated image restrictions, warranty or safety risks, or regulatory revalidation burdens.
• Control objectives: what you must prevent, detect, or contain (e.g., block remote code execution from untrusted networks).
• Selected compensating controls: precise configurations, rule sets, and operational procedures, including Network Segmentation and Access Monitoring.
• Framework mapping: align to applicable compliance frameworks and internal policies; note relevant FDA guidance considerations.
• Implementation plan: change tickets, approvals, maintenance windows, rollback steps, and communication to clinical staff.
• Control validation plan and results: methods, test dates, evidence, and defects remedied.
• Residual risk statement: before/after ratings, assumptions, expiry date, and acceptance by the accountable authority.
• Monitoring and maintenance: log sources, alert thresholds, review cadence, and responsible teams.
• Replacement or remediation path: conditions to remove the exception (patch availability, device retirement, or redesign).

Validation of Controls

Control validation verifies that your safeguards are effective and operating as designed. For legacy medical devices, prioritize non-invasive tests that do not disrupt clinical workflows while still proving that risky pathways are closed and events are detectable.

Recommended validation methods

• Functional tests: confirm only approved protocols and peers can reach the device; attempt blocked actions to ensure denial.
• Adversarial simulation: safe, scoped attempts to exploit representative weaknesses; validate alerting and containment.
• Configuration and rule reviews: peer review of firewall policies, allowlists, PAM settings, and NAC posture checks.
• Monitoring exercises: generate test events to confirm log capture, parsing, correlation, and on-call response.
• Independent review: clinical engineering and security jointly sign off; quality/compliance verifies evidence integrity.

Acceptance criteria and evidence

• Measurable objectives (e.g., “deny all but approved subnets and services”).
• Pass/fail results tied to each objective, with timestamps and screenshots or config exports.
• Control health metrics: drift checks, MTTD/MTTR targets, and periodic revalidation dates for ongoing control validation.

Residual Risk Assessment

Residual risk is the level of risk that remains after compensating controls are in place. You should calculate it with the same rigor as your initial assessment, explicitly documenting assumptions, limitations, and exposure time.

How to assess residual risk

• Describe the threat scenario and impact on patient safety and operations.
• Estimate likelihood with controls applied, considering attacker effort, required access, and monitoring coverage.
• Rate impact, including safety severity, data confidentiality, system availability, and regulatory repercussions.
• Record uncertainty and dependencies (e.g., a firewall rule or NAC posture state).
• Decide acceptability per risk appetite; if not acceptable, layer additional controls or restrict device use.

Communication and time limits

Set an explicit review or expiry date for the residual risk acceptance. Note triggers that force reassessment, such as new exploits, clinical workflow changes, or a vendor patch becoming available.

Accountability and Review

Clear ownership prevents “set-and-forget” controls. Define who is responsible for implementing, operating, reviewing, and approving the exception and its compensating controls.

• Device owner (clinical): accountable for safe use and local procedures.
• Security/network teams: responsible for implementation, monitoring, and incident response.
• Clinical engineering/biomed: coordinates maintenance, service access, and vendor interactions.
• Compliance/quality/privacy: ensures alignment with policies, documentation standards, and regulatory expectations.
• Executive approver: accepts residual risk and budget for remediation or replacement.

Establish a review cadence (e.g., quarterly validation, monthly log checks, annual re-approval) and event-driven reviews after incidents, major network changes, or firmware updates. Keep evidence centralized and audit-ready.

Network Segmentation Strategies

Segmentation limits exposure by tightly scoping where the device can communicate. Start with a data-flow map, then build allowlists that reflect only clinically necessary connections and services.

• VLAN and ACL zoning: isolate devices by function and criticality; apply deny-by-default rules at inter-VLAN gateways.
• Firewall or microsegmentation: enforce per-device or per-group policies; restrict east–west traffic and lateral movement.
• NAC and posture control: admit devices only to the correct segment; quarantine unknown or non-compliant endpoints.
• Brokered access: jump hosts, bastion services, or remote support gateways with session recording for vendors.
• Virtual patching: intrusion prevention and protocol-aware inspection to block known exploits and unsafe commands.

Document topology diagrams, rule references, and change tickets so reviewers can trace each segmentation decision back to risks and compliance frameworks.

Access Controls and Monitoring

Harden identity and access around the device, then continuously watch for misuse. Where the device cannot support modern controls, wrap it with compensating gateways and strict operational procedures.

• Least privilege: unique accounts, role-based access, and time-bound elevation via PAM; vendor access through controlled pathways.
• Strong authentication: MFA for remote sessions; credential vaulting and rotation; disable shared or default accounts when feasible.
• Operational safeguards: break-glass procedures with immediate post-use review; change control for any configuration alteration.
• Access monitoring: centralize logs in a SIEM, baseline normal activity, and alert on anomalies and policy violations.
• Telemetry alternatives: use passive network monitoring when the device cannot generate adequate logs.

Conclusion

When legacy medical devices can’t be patched, you document compensating controls by defining targeted objectives, implementing tight network segmentation and access controls, validating effectiveness, and recording residual risk with clear accountability. Align your records to documentation standards, compliance frameworks, and FDA guidance, and revisit them on a fixed cadence to keep patients and operations safe.

FAQs

What information is required when documenting compensating controls?

Capture the asset identity, vulnerability details, why patching is infeasible, control objectives, selected safeguards with exact configurations, framework and FDA guidance references, implementation approvals, control validation results, residual risk and acceptance, monitoring procedures, review cadence, and the plan to retire or remediate the exception.

How can residual risk be assessed for legacy medical devices?

Describe the threat scenario, re-estimate likelihood with controls in place, rate multi-dimensional impact (including patient safety), note assumptions and uncertainties, and compare the result to your risk appetite. If the residual risk is still too high, add controls, restrict clinical use, or accelerate device replacement.

What methods validate compensating controls’ effectiveness?

Use functional allow/deny tests, safe adversarial simulations, rule and configuration reviews, and monitoring exercises that generate test events. Define acceptance criteria up front and collect evidence—logs, screenshots, and change records—to prove continued control validation over time.

How does FDA guide compensating controls for medical devices?

FDA guidance expects a risk-based approach that prioritizes patient safety, clear rationale when patching is not feasible, and documented mitigations proportionate to the hazard. Your file should show how controls reduce exposure, how you validate them, and how you monitor and re-evaluate residual risk as conditions change.